Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

ALS biomarker hunt aims to boost failed drug trials

NCT ID NCT02360891

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study of 500 people with ALS (Lou Gehrig's disease) aimed to find biological signs, or biomarkers, that can predict how the disease will progress. Researchers collected clinical, imaging, and lab data to better understand different forms of ALS. The goal is to help future drug trials select the right patients and improve chances of success.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify which patients might respond to certain treatments, making future ALS drug trials more effective.
What could go wrong
This is an observational study, not a treatment trial. It may not directly lead to new therapies, and the biomarkers found may not be reliable enough to change clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

500 people

The number who actually took part.

Started

Jan 2015

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Multicentric French cohort of 1000 ALS patients, 100 neurological controls and 200 healthy controls

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for ALS patients: * Patients with suspicion of Amyotrophic lateral sclerosis * Since the first signs (cramps fasciculation) or first deficit at the diagnosis work up * Patient older than 18 years * Patient able to provide informed consent Inclusion Criteria for healthy controls: * Subjects older than 18 years (matched population for age and sex with ALS) * Neurological testing and examination showing no neurological disorders. * Not having severe disease or life- functional prognosis Inclusion Criteria for neurological controls: * Patients having a typical neurodegenerative diseases other than ALS (Parkinson's disease, Alzheimer's disease) * Not having severe disease or life- functional prognosis * Patient older than 18 years (matched population for age and sex with ALS) * Patient able to provide informed consent Exclusion Criteria: * Subjects younger than 18 years * Patient unable to provide informed consent * Having severe disease or life- functional prognosis * Contraindications MRI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amyotrophic lateral sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis motor neuron disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Amyotrophic lateral sclerosis Motor neuron disease

Contacts and locations

Locations

  • AP-HM,Hôpital de la Timone

    Marseille, France

  • CHRU, Hôpital Salengro

    Lille, France

  • CHU Bretonneau

    Tours, France

  • CHU Cote de Nacre

    Caen, France

  • CHU Gabriel Montpied

    Clermont-Ferrand, France

  • CHU Pontchaillou

    Angers, France

  • Centre Hospitalier

    Saint-Brieuc, France

  • Hôpital Dupuytren

    Limoges, France

  • Hôpital Gui de Chauliac

    Montpellier, France

  • Hôpital La Pitié (AP-HP)

    Paris, France

  • Hôpital Neurologique Pierre Wertheimer

    Lyon, France

  • Hôpital Nord

    Saint-Etienne, France

  • Hôpital de l'Archet 1, CHU

    Nice, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.